Mircera Continuous Erythropoiesis Receptor Activator: Phase III data

In the open-label Phase III ARCTOS trial in 324 CKD patients not on dialysis, CERA

Read the full 153 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE